DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20150875

Study on the safety profile of Latanoprost and Timolol in primary open angle glaucoma

Sharadashri Rao, P. V. Narayanan

Abstract


Background: Topical beta blockers, Timolol and the prostaglandin F2α analogue Latanoprost are the most common prescribed medications as first line therapy. Their safety profiles have to be compared to justify the same. The objectives of this study were to compare the safety profile of Latanoprost with that of Timolol in the treatment of primary open angle glaucoma.

Methods: In this randomized open label 12-week study, 60 patients were randomized to receive either 0.005% of Latanoprost once daily in the evening or 0.5% of Timolol twice daily. Their safety was concluded by monitoring their adverse effects during follow-up visits at 2, 4, 6, and 12 weeks.

Results: Bradycardia was seen only in Timolol group whereas ocular adverse effects such as periocular pigmentation, the growth of eyelashes, and conjunctival hyperemia were seen only in Latanoprost group. Ocular discomfort was present equally in both the groups. Foreign body sensation was seen in both the groups, but it was more frequent in Latanoprost group. The blurring of vision was predominantly seen in Timolol group. Corneal anesthesia was seen in one of the patients on Timolol.

Conclusions: The incidence of adverse effects was not significantly different between Latanoprost and Timolol therapy. Both had favorable safety profiles. However, Latanoprost has safer systemic side effects profile when compared to Timolol. 


Keywords


Beta blocker,Intraocular pressure, Prostaglandin analogue

Full Text:

PDF

References


Stamper RL, Lieberman MF, Drake MV. Becker and Shaffer’s: Diagnosis and Therapy of Glaucomas. 8th Edition. Philadelphia: Mosby, Elsevier; 2009: 8-20,47-62,239-58,359-71,376-87.

Lang GK. Glaucoma. Ophthalmology: A Short Textbook. Ch. 10. New York: Thieme Medical Publishers; 2000: 233-78.

Hazin R, Hendrick AM, Kahook MY. Primary open-angle glaucoma: diagnostic approaches and management. J Natl Med Assoc. 2009;101(1):46-50.

Halpern MT, Covert DW, Robin AL. Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects. Trans Am Ophthalmol Soc. 2002;100:109-17.

Altan-Yaycioglu R, Türker G, Akdöl S, Acunas G, Izgi B. The effects of beta-blockers on ocular blood flow in patients with primary open angle glaucoma: a color Doppler imaging study. Eur J Ophthalmol. 2001;11(1):37-46.

Pillunat LE, Larsson LI; European and Canadian Latanoprost Study Group. Intraocular pressure after replacement of current dual therapy with latanoprost monotherapy in patients with open angle glaucoma. Br J Ophthalmol. 2003;87(12):1492-6.

Lodhi AA, Talpur KI, Khanzada MA. Latanoprost 0.005% v/s timolol maleate 0.5% pressure lowering effect in primary open angle glaucoma. Pak J Ophthalmol. 2008;24(2):68-70.

Darhad U, Nakamura M, Fujioka M, Tatsumi Y, Nagai-Kusuhara A, Maeda H, et al. Intraocular pressure lowering effect of once daily versus once weekly latanoprost instillation in the same normal individuals. Kobe J Med Sci. 2008;53(6):297-304.

Lawlor D, Toris CB, Camras CB. Glaucoma. Science and practice. In: Morrison JC, Pollack IP, editors. Prostaglandin Analogs. New York: Thieme Medical Publishers; 2003: 391-8.

Dutta LC. Glaucoma. Modern Ophthalmology. 3rd Edition., Vol. 1. New Delhi: Jaypee Publishers; 2013: 477-80,487-506,574-84,586-93.

Tielsch JM, Katz J, Sommer A, Quigley HA, Javitt JC. Family history and risk of primary open angle glaucoma. The Baltimore eye survey. Arch Ophthalmol. 1994;112(1):69-73.

Ponte F, Giuffré G, Giammanco R, Dardanoni G. Risk factors of ocular hypertension and glaucoma. The casteldaccia eye study. Doc Ophthalmol. 1994;85:203-10.

Khurana AK, Khurana B. Glaucoma. Comprehensive Ophthalmology. 5th Edition., Ch. 9. New Delhi: New Age International; 2007: 217-56.

Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132(4):472-84.

Orouk WM, Abdel Salam SN. Intraocular pressure reducing effect of latanoprost versus timolol in patients with open angle glaucoma and ocular hypertension. Suez Canal Univ Med J. 2000;3(2):213-7.

Ravinet E, Mermoud A, Brignoli R. Four years later: a clinical update on latanoprost. Eur J Ophthalmol. 2003;13(2):162-75.